Xenon Pharmaceuticals Inc
Statements
Cash Flow
Xenon Pharmaceuticals Inc (XENE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -95 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.5 | -4.7 | -6.5 | -6.8 | -8.6 | -6.8 | -8.2 | -5.5 | -14 | -7.2 | -8.7 | -8.6 | -7.1 | 20 | -13 | -10 | -12 | -13 | -21 | -13 | -15 | -21 | -18 | -17 | -30 | -33 | -34 | -33 | -42 | -35 | -46 | -33 | -50 | -54 | -62 | -64 | -72 | -81 | -89 | -95 | -338 | |
| 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.6 | 1.7 | 0.9 | 0.6 | 0.7 | 0.7 | 0.6 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 2.4 | |
| 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.6 | 0.5 | 0.5 | 0.6 | 1.4 | 1.0 | 1.5 | 1.6 | 1.6 | 2.0 | 2.7 | 2.6 | 2.7 | 3.6 | 5.2 | 5.7 | 5.8 | 6.0 | 8.5 | 8.7 | 9.2 | 9.4 | 15 | 13 | 14 | 12 | 14 | 14 | 14 | 17 | 17 | 61 | |
| 1.1 | 1.2 | 0.2 | 0.1 | -0.2 | 0.7 | -3.5 | 0.8 | 0.6 | 1.0 | 0.5 | 0.2 | 0.6 | 1.2 | 1.3 | 1.6 | 1.2 | 1.8 | 1.8 | 2.9 | 2.8 | 3.6 | 7.1 | 7.0 | 3.9 | 5.1 | 6.3 | 6.7 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.9 | 0.0 | 0.7 | 0.3 | -0.9 | 0.4 | -1.2 | 1.2 | 0.0 | 0.1 | 2.0 | 0.9 | 1.0 | 30 | -7.1 | -12 | -4.3 | -2.8 | -7.0 | 5.9 | -2.6 | 1.0 | -6.2 | 6.9 | -2.4 | 1.1 | 2.6 | 6.9 | -3.3 | -0.5 | -5.9 | 0.9 | -0.3 | 2.2 | -12 | 2.6 | 5.0 | 9.0 | -3.4 | 2.4 | 13 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.0 | 0.2 | 0.3 | 0.3 | 0.0 | 0.6 | 0.6 | 0.4 | 0.8 | 0.8 | 0.4 | 0.9 | 0.2 | 0.5 | 0.2 | 0.5 | 0.4 | 1.8 | 2.2 | 2.1 | 1.2 | 0.1 | 0.2 | 1.5 | 0.6 | 0.8 | 0.0 | 0.2 | 0.3 | 0.3 | 0.1 | 0.3 | 1.0 | |
| -0.1 | -32 | 9.2 | 9.3 | -0.1 | 5.8 | 5.0 | 1.9 | -23 | -13 | -7.0 | -6.7 | 7.7 | -60 | -53 | 12 | -19 | 43 | -55 | 8.2 | 16 | -215 | -49 | 1.3 | -234 | -14 | 47 | 28 | 48 | -240 | -43 | 111 | 0.5 | 99 | 35 | 82 | 39 | 63 | -407 | -331 | -637 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 24 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 29 | 74 | 0.0 | 0.1 | 0.0 | 0.0 | 27 | 102 | – | – | – | 0.1 | 0.1 | 0.0 | 0.0 | – | – | 0.7 | -75 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 6.9 | 6.9 | 6.9 | 6.9 | 6.9 | 5.0 | 5.0 | 3.5 | 8.5 | – | – | -17 | -17 | -17 | -17 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 24 | 0.0 | 0.2 | 0.0 | 0.2 | 6.9 | 0.1 | 34 | 77 | 0.0 | 0.1 | 0.0 | 0.0 | 27 | 102 | -18 | 2.4 | 0.0 | 119 | 0.1 | 4.8 | 324 | 7.9 | 270 | 0.7 | 0.0 | 0.0 | 0.0 | 30 | 324 | 0.0 | 0.0 | 0.0 | 12 | 1.2 | 0.1 | 2.4 | 114 | 843 | 0.0 | 959 | |
| 19 | -37 | 3.1 | 2.9 | -8.4 | 5.8 | -3.3 | 30 | 41 | -20 | -16 | -15 | 0.6 | -13 | 36 | -16 | -29 | 30 | 43 | -5.1 | 4.9 | 88 | -59 | 253 | -266 | -46 | 12 | -5.0 | 35 | 49 | -90 | 78 | -49 | 55 | -26 | 19 | -31 | 95 | 347 | -426 | -16 | |
| -4.6 | -4.7 | -6.6 | -6.9 | -8.6 | -6.9 | -8.4 | -5.7 | -14 | -7.4 | -9.0 | -8.9 | -7.1 | 19 | -14 | -11 | -13 | -14 | -21 | -14 | -15 | -21 | -19 | -17 | -31 | -34 | -37 | -35 | -43 | -36 | -46 | -34 | -50 | -55 | -62 | -64 | -72 | -82 | -89 | -96 | -339 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.